Short-term synaptic plasticity.

Short-term synaptic plasticity.

Synaptic transmission is a dynamic course of. Postsynaptic responses wax and wane as presynaptic exercise evolves. This distinguished attribute of chemical synaptic transmission is an important determinant of the response properties of synapses and, in flip, of the stimulus properties chosen by neural networks and of the patterns of exercise generated by these networks. This evaluation focuses on synaptic modifications that outcome from prior exercise within the synapse below research, and is restricted to short-term results that final for at most a couple of minutes.

Forms of synaptic enhancement, equivalent to facilitation, augmentation, and post-tetanic potentiation, are normally attributed to results of a residual elevation in presynaptic [Ca(2+)]i, appearing on a number of molecular targets that seem like distinct from the secretory set off chargeable for quick exocytosis and phasic launch of transmitter to single motion potentials. We talk about the proof for this speculation, and the origins of the totally different kinetic phases of synaptic enhancement, in addition to the interpretation of statistical modifications in transmitter launch and roles performed by different elements equivalent to alterations in presynaptic Ca(2+) inflow or postsynaptic ranges of [Ca(2+)]i. Synaptic melancholy dominates enhancement at many synapses.

Depression is normally attributed to depletion of some pool of readily releasable vesicles, and numerous types of the depletion mannequin are mentioned. Depression may come up from suggestions activation of presynaptic receptors and from postsynaptic processes equivalent to receptor desensitization. In addition, glial-neuronal interactions can contribute to short-term synaptic plasticity. Finally, we summarize the current literature on putative molecular gamers in synaptic plasticity and the consequences of genetic manipulations and different modulatory influences.

Primary construction of the Aequorea victoria green-fluorescent protein.

Many cnidarians make the most of green-fluorescent proteins (GFPs) as energy-transfer acceptors in bioluminescence. GFPs fluoresce in vivo upon receiving vitality from both a luciferase-oxyluciferin excited-state advanced or a Ca(2+)-activated phosphoprotein. These extremely fluorescent proteins are distinctive because of the chemical nature of their chromophore, which is comprised of modified amino acid (aa) residues throughout the polypeptide. This report describes the cloning and sequencing of each cDNA and genomic clones of GFP from the cnidarian, Aequorea victoria.

The gfp10 cDNA encodes a 238-aa-residue polypeptide with a calculated Mr of 26,888. Comparison of A. victoria GFP genomic clones reveals three totally different restriction enzyme patterns which means that at the least three totally different genes are current within the A. victoria inhabitants at Friday Harbor, Washington. The gfp gene encoded by the lambda GFP2 genomic clone is comprised of at the least three exons unfold over 2.6 kb. The nucleotide sequences of the cDNA and the gene will help within the elucidation of structure-function relationships on this distinctive class of proteins.

Citations in CAS SciFinder to the rule-of-five (RO5) publication will exceed 1000 by year-end 2004. Trends within the RO5 literature explosion that may be discerned are the additional definitions of drug-like. This matter is explored when it comes to drug-like physicochemical options, drug-like structural options, a comparability of drug-like and non-drug-like in drug discovery and a dialogue of how drug-like options relate to medical success. Physicochemical options of CNS medicine and options associated to CNS blood-brain transporter affinity are briefly reviewed. Recent literature on options of non-oral medicine is reviewed and the way options of lead-like compounds differ from these of drug-like compounds is mentioned.

Short-term synaptic plasticity.

In vitro molecular mechanisms of bisphenol A motion.

Bisphenol A (BPA, 2,2-bis (4-hydroxyphenyl) propane; CAS# 80-05-7) is a chemical used primarily within the manufacture of polycarbonate plastic, epoxy resins and as a non-polymer additive to different plastics. Recent proof has demonstrated that human and wildlife populations are uncovered to ranges of BPA which trigger adversarial reproductive and developmental results in various totally different wildlife species and laboratory animal fashions. However, there are main uncertainties surrounding the spectrum of BPA’s mechanisms of motion, the tissue-specific impacts of exposures, and the essential home windows of susceptibility throughout which goal tissues are delicate to BPA exposures.

As a basis to handle a few of these uncertainties, this evaluation was ready by the “In vitro” professional sub-panel assembled in the course of the “Bisphenol A: An Examination of the Relevance of Ecological, In vitro and Laboratory Animal Studies for Assessing Risks to Human Health” workshop held in Chapel Hill, NC, Nov 28-29, 2006. The particular cost of this professional panel was to evaluation and assess the energy of the revealed literature pertaining to the mechanisms of BPA motion. The ensuing doc is an in depth evaluation of revealed research which have centered on the mechanistic foundation of BPA motion in various experimental fashions and an evaluation of the energy of the proof relating to the revealed BPA analysis.

In its present state, the database employs an easy-to-use, searchable interface for acquiring detailed information on the 109 at present recognized RNA modifications. Each entry gives the chemical construction, frequent identify and image, elemental composition and mass, CA registry numbers and index identify, phylogenetic supply, sort of RNA species wherein it’s discovered, and references to the primary reported construction willpower and synthesis. Though newly transferred in its entirety to The RNA Institute, the RNAMDB continues to develop with two notable additions, agmatidine and 8-methyladenosine, appended within the final 12 months.

Anti-CD19-ScFv-CD28-CD3ζ (no marker)

LVP1449 1x10^8 IFU/ml x 200ul
EUR 455
Description: Anti-CD19 CAR Lentivirus with human CD28 stimulatory domain, do not contain any selection marker.

CAR negative control: Anti-CD19-ScFv- CD28 (Puro)

CAR-ctr4 1x10^8 IFU/ml x 200ul
EUR 276.5
Description: Anti-CD19 (CD28) CAR control lentivirus without activation domain, containing Puromycin selection

Anti-CD19-ScFv-4-1BB-CD3ζ (Bsd)

LVP1441 1x10^8 IFU/ml x 200ul
EUR 455
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing Blasticidin selection

Anti-CD19-ScFv-4-1BB-CD3ζ (Puro)

LVP1440 1x10^8 IFU/ml x 200ul
EUR 455
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing Puromycin selection.

Anti-CD19-ScFv-4-1BB-CD3ζ (no marker)

LVP1444 1x10^8 IFU/ml x 200ul
EUR 455
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, do not contain any selection marker.

Anti-CD19-ScFv-4-1BB-CD3ζ (GFP-Puro)

LVP1442 1x10^8 IFU/ml x 200ul
EUR 455
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing GFP-Puromycin dual selection.

Anti-CD19-ScFv-4-1BB-CD3ζ (RFP-Puro)

LVP1443 1x10^8 IFU/ml x 200ul
EUR 455
Description: Anti-CD19 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing RFP-Puromycin dual selection.

CAR negative control: Anti-CD19-ScFv-4-1BB (Puro)

CAR-ctr2 1x10^8 IFU/ml x 200ul
EUR 276.5
Description: Anti-CD19 (4-1BB) control lentivirus without activation domain, containing Puromycin selection

Anti-CD19_CD20-ScFv- CD28-CD3ζ (Puro) Lentivirus

LVP1645 1x10^8 IFU/ml x 200ul
EUR 553
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human CD28 stimulatory domain, containing puromycin antibiotic selection

Anti-CD19_CD20-ScFv- CD28-CD3ζ (No Select) Lentivirus

LVP1644 1x10^8 IFU/ml x 200ul
EUR 553
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human CD28 stimulatory domain, do not contain antibiotic selection

Anti-CD19_CD20-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus

LVP1646 1x10^8 IFU/ml x 200ul
EUR 553
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection

Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ)

79853 2 vials
EUR 10340
Description: Anti-CD19 CAR/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR and NFAT-luciferase reporter. It is made from the anti-CD19 CAR lentivirus (BPS Bioscience #79851). The reporter cell line has been validated for anti CD19-CAR expression by FACS, and for luciferase reporter activation stimulated by target cells including CD19/CHO recombinant cell line can be used for primary screening and functional validation of anti-CD19 CAR construct and lentivirus before testing in primary T cells.

Anti-CD19 CAR consists of anti-CD19 scFv linked to 3rd generation CAR (Chimeric Antigen Receptor) containing CD28, 4-1BB co-stimulatory domains, and CD3ζ signaling domain.

Anti-CD19_CD20-ScFv-4-1BB-CD3ζ (Puro) Lentivirus

LVP1642 1x10^8 IFU/ml x 200ul
EUR 553
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing puromycin antibiotic selection

Anti-CD19_CD20-ScFv-4-1BB-CD3ζ (No Select) Lentivirus

LVP1641 1x10^8 IFU/ml x 200ul
EUR 553
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, do not contain antibiotic selection

Anti-CD19_CD20-ScFv-4-1BB-CD3ζ (GFP-Puro) Lentivirus

LVP1643 1x10^8 IFU/ml x 200ul
EUR 553
Description: Bispecific Anti-CD19/CD20 CAR Lentivirus with human 4-1BB (CD137) stimulatory domain, containing GFP-Puromycin dual selection

Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ)

78600 50 µl
EUR 1150
Description: The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. These viruses constitutively express the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge, 4-1BB, and CD3ζ signaling domains. 

Anti-CD28 Antibody [CD28.2], PE-25Tests

QAB37-PE-25Tests 25Tests
EUR 169.2

Anti-CD28 Antibody [CD28.2], APC-25Tests

QAB37-APC-25Tests 25Tests
EUR 188.4

Anti-CD28 Antibody [CD28.2], PE-100Tests

QAB37-PE-100Tests 100Tests
EUR 270

Anti-CD28 Antibody [CD28.2], APC-100Tests

QAB37-APC-100Tests 100Tests
EUR 310.8

Anti-CD28 Antibody [CD28.2], FITC-25Tests

QAB37-F-25Tests 25Tests
EUR 157.2

Anti-CD28 Antibody [CD28.2], FITC-100Tests

QAB37-F-100Tests 100Tests
EUR 240

Anti-CD28 Antibody [CD28.2], Qfluor 630-100ug

QAB37-QF630-100ug 100ug
EUR 259.2

Anti-CD28 Antibody [CD28.2], Unconjugated-100ug

QAB37-100ug 100ug
EUR 169.2

Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector)

78601 50 µl
EUR 1150
Description: The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, 4-1BB and CD3ζ signaling domains .Note: This product transduces the same construct as the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ) (BPS Bioscience #78600), but differs in key aspects:78601 is constructed with a SIN lentivector while 78600 is not. 78601 does not contain an antibiotic for selection while 78600 contains a puromycin selection so the transduced cells can be selected with puromycin.

Anti-CD28 Antibody [CD28.2], PE-Cy7-25Tests

QAB37-PE7-25Tests 25Tests
EUR 199.2

Anti-CD28 Antibody [CD28.2], PerCP-Cy5.5-100Tests

QAB37-PCP55-100Tests 100Tests
EUR 381.6

Anti-CD28 Antibody [CD28.2], PerCP-Cy5.5-25Tests

QAB37-PCP55-25Tests 25Tests
EUR 229.2

Anti-CD28 Antibody [CD28.2], PE-Cy7-100Tests

QAB37-PE7-100Tests 100Tests
EUR 340.8

Anti-CD3/CD28 stimulus for human PBMC

CT372 50 tests
EUR 141.6

Anti-CD19/CD22 Bispecific CAR Lentivirus (Clones FMC63/m971 ScFv-CD8-4-1BB-CD3ζ)

78609 50 µl
EUR 1095
Description: The anti-CD19/CD22 Bispecific CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragments) of anti-CD19 (clone FMC63) and anti-CD22 (clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains.

CAR negative control: CD28-CD3ζ (Puro)

CAR-ctr3 1x10^8 IFU/ml x 200ul
EUR 276.5
Description: CAR-T CD28 control lentivirus without targeting domain, containing Puromycin selection

Anti-BCMA-ScFv- CD28-CD3ζ (Puro) Lentivirus

LVP1651 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-BCMA CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection.

Anti-CD28

E40YR1618 1 mg
EUR 2960
Description: Available in various conjugation types.

anti-CD28

YF-PA10780 50 ug
EUR 435.6
Description: Mouse polyclonal to CD28

Hamster Anti CD28 Antibody

20-abx137056
  • Ask for price
  • Ask for price
  • 0.5 mg
  • 1 mg

Anti-h CD22-ScFv- CD28-CD3ζ (Puro) Lentivirus

LVP1663 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h CD22 CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection.

Absolute Mcell™ Anti-CD3/CD28 Antibody Magnetic Particles, 5.5 µm, DMF Filed, Sterile

WHM-AB23-095 2.5 mg
EUR 850

Anti-h HER2-ScFv- CD28-CD3ζ (Puro) Lentivirus

LVP1657 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h HER2 CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection.

Anti-h TGFb-ScFv- CD28-CD3ζ (Puro) Lentivirus

LVP1675 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h TGFb CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection.

Hamster Anti CD28 FITC Antibody

20-abx137135
  • Ask for price
  • Ask for price
  • 0.5 mg
  • 1 mg

Anti-BCMA-ScFv- CD28-CD3ζ (No Select) Lentivirus

LVP1650 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-BCMA CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection.

Anti-BCMA-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus

LVP1652 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-BCMA CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection.

Anti-CD28 Antibody

E38A8582 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-CD28 Antibody

E38A8787 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-CD28 Antibody

ER2001-42 100ul
EUR 189
Description: CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. T cell stimulation through CD28 in addition to the T-cell receptor (TCR) can provide a potent signal for the production of various interleukins (IL-6 in particular). CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins. When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen-presenting cells (APCs). The CD86 expression on antigen-presenting cells is constitutive (expression is independent of environmental factors). CD28 is the only B7 receptor constitutively expressed on naive T cells. Association of the TCR of a naive T cell with MHC:antigen complex without CD28:B7 interaction results in a T cell that is anergic.

Anti-CD28 antibody

STJ16100044 100 µg
EUR 424.8

Anti-CD28 antibody

STJ72503 100 µg
EUR 430.8

Anti-CD28 antibody

STJ119563 100 µl
EUR 332.4
Description: The protein encoded by this gene is essential for T-cell proliferation and survival, cytokine production, and T-helper type-2 development. Several alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Anti-CD28 antibody

STJ96609 200 µl
EUR 236.4
Description: Rabbit polyclonal to CD28.

Anti-CD28 Antibody

A00065 0.1mg
EUR 449
Description: Boster Bio Anti-CD28 Antibody (Catalog # A00065). Tested in ELISA, WB, IHC, IF applications. This antibody reacts with Human.

Anti-CD19 CAR negative control/ NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 transmembrane motif)

79854 2 vials
EUR 1650
Description: Anti-CD19 CAR negative control/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR negative control and NFAT-luciferase reporter. The anti-CD19 CAR negative control consists of anti-CD19 scFv linked to the CD28 transmembrane motif without any intracellular signaling domains. The reporter cell line has been validated for anti- CD19 expression by FACS, while the stimulation by target cells including CD19/CHO recombinant cell line has not activated the luciferase reporter gene in this cell line. The cell line can be used for the negative control of anti-CD19 CAR/Jurkat-NFAT cell line (BPS Bioscience, #79853)._x000D_ _x000D_

Anti-h CD22-ScFv- CD28-CD3ζ (No Select) Lentivirus

LVP1662 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h CD22 CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection.

Anti-h CD22-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus

LVP1664 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h CD22 CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection.

Hamster Anti CD28 Biotinylated Antibody

20-abx137134
  • Ask for price
  • Ask for price
  • 0.5 mg
  • 1 mg

Anti-h HLA-A2-ScFv- CD28-CD3ζ (Puro) Lentivirus

LVP1669 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h HLA-A2 CAR Lentivirus with human CD28 stimulatory domain, containing Puromycin antibiotic selection.

Anti-h HER2-ScFv- CD28-CD3ζ (No Select) Lentivirus

LVP1656 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h HER2 CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection.

Anti-h TGFb-ScFv- CD28-CD3ζ (No Select) Lentivirus

LVP1674 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h TGFb CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection.

Anti-h HER2-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus

LVP1658 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h HER2 CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection.

Anti-h TGFb-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus

LVP1676 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h TGFb CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection.

Goat Anti-CD28 Antibody

TA311351 100 µg Ask for price

Goat Anti-Cd28 Antibody

TA311383 100 µg Ask for price

Goat anti-CD28 Antibody

dAP-2339 50ug
EUR 264.6

Mouse anti-CD28 Antibody

DL99412A-100ul 100 ul
EUR 299
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28

Mouse anti-CD28 Antibody

DL99412A-50ul 50 ul
EUR 210
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28

Anti-Cd28 (mouse) antibody

STJ72504 100 µg
EUR 430.8

Anti-CD28 Agonist Antibody

100182-1 50 µg
EUR 335
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. This antibody crosslinked with FcGR2B is useful for activation of CD27 costimulatory pathway in T cells.

Anti-CD28 Agonist Antibody

100182-2 100 µg
EUR 460
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species.

CAR negative control: CD28-CD3ζ (No Select) Lentivirus

CAR-ctr6 1x10^8 IFU/ml x 200ul
EUR 276.5
Description: CAR (CD28) control lentivirus without targeting domain, does not contain any antibiotic selection

CAR negative control: CD28-CD3ζ (GFP-Puro) Lentivirus

CAR-ctr8 1x10^8 IFU/ml x 200ul
EUR 276.5
Description: CAR (CD28) control lentivirus without targeting domain, containing GFP-Puromycin dual selection

Goat anti-Cd28 (mouse) Antibody

dAP-2313 50ug
EUR 264.6

Anti-CD28 Antibody Picoband™

A00065-3 10ug
EUR 154
Description: Western blot, 0.25-0.5 μg/ml, Human;_x000D_Flow Cytometry, 1-3 μg/1x106 cells, Human;_x000D_Direct ELISA, 0.1-0.5 μg/ml, Human

Anti-h HLA-A2-ScFv- CD28-CD3ζ (No Select) Lentivirus

LVP1668 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h HLA-A2 CAR Lentivirus with human CD28 stimulatory domain, does not contain any antibiotic selection.

Rabbit anti-CD28 (pY218) Antibody

DL90184A-100ul 100 ul
EUR 299
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28

Rabbit anti-CD28 (pY218) Antibody

DL90184A-50ul 50 ul
EUR 209.3
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28

Rabbit anti-CD28 (pY218) Antibody

YLD1497-100ul 100 ul
EUR 320
Description: Rabbit polyclonal antibody to CD28 (pY218)

Rabbit anti-CD28 (pY218) Antibody

YLD1497-50ul 50 ul
EUR 200
Description: Rabbit polyclonal antibody to CD28 (pY218)

Anti-h HLA-A2-ScFv- CD28-CD3ζ (GFP-Puro) Lentivirus

LVP1670 1x10^8 IFU/ml x 200ul
EUR 553
Description: Anti-h HLA-A2 CAR Lentivirus with human CD28 stimulatory domain, containing GFP-Puromycin dual selection.

Syrian Hamster anti-CD28 Antibody

DL99429A-100ul 100 ul
EUR 299
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28

Syrian Hamster anti-CD28 Antibody

DL99429A-50ul 50 ul
EUR 210
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28

Anti-CD30 / TNFRSF8 Antibody (CD30/412)

A1484-100 each
EUR 574.8

Anti-CD28 Reference Antibody (FR104)

E24CHA679 100 μg
EUR 225
Description: Available in various conjugation types.

Anti-CD28 Agonist Antibody (Humanized)

100186-1 50 µg
EUR 345
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. This antibody crosslinked with FcGR2B is useful for activation of CD27 costimulatory pathway in T cells. This antibody has been humanized to reduce immunogenicity and improve the therapeutic half-life.

Anti-CD28 Agonist Antibody (Humanized)

100186-2 100 µg
EUR 475
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. This antibody has been humanized to reduce immunogenicity and improve the therapeutic half-life.

Anti-CD16/CD32 Antibody

E38A8954 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-CD40/Cd40 Antibody

A00068-1 100ug/vial
EUR 352.8

Anti-CD16+CD32 antibody

MO16A(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16A(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16B(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16B(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16CFB(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16CFB(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16F(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16F(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16F(V500) 500 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PE(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PE(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PP(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PP(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PP5.5(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PP5.5(V25) 25 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PU(V100) 100 ug
EUR 60

Anti-CD16+CD32 antibody

MO16PU(V500) 500 ug
EUR 60

Anti-CD70/Cd27L Antibody

A02853 100ul
EUR 476.4
Description: Rabbit Polyclonal CD70/Cd27L Antibody. Validated in WB and tested in Human.

Rat anti-CD16/CD32 Antibody

DL99452A-100ul 100 ul
EUR 299
Description: CD32; FCG2; IGFR2; Low affinity immunoglobulin gamma Fc region receptor II-b; IgG Fc receptor II-b; CDw32; Fc-gamma RII-b; Fc-gamma-RIIb; FcRII-b; CD32

Rat anti-CD16/CD32 Antibody

DL99452A-50ul 50 ul
EUR 210
Description: CD32; FCG2; IGFR2; Low affinity immunoglobulin gamma Fc region receptor II-b; IgG Fc receptor II-b; CDw32; Fc-gamma RII-b; Fc-gamma-RIIb; FcRII-b; CD32

Anti-CD59/Cd59a Antibody

A00914 100ug/vial
EUR 400.8

Anti-CD22 CAR Lentivirus (Clone m971 ScFv-CD8-4-1BB-CD3ζ)

78608 50 µl
EUR 1095
Description: The anti-CD22 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD22 (clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (below).

Anti-CD40L/CD40LG Antibody

A01114-1 100ug/vial
EUR 352.8

Anti-CD40L/Cd40lg Antibody

A01114-2 100ug/vial
EUR 400.8

Anti-CD40L/CD40LG Antibody

A01114-3 100ug/vial
EUR 352.8

Anti-CD16/CD32, Rat IgG2b Antibody

A1106-200 each
EUR 874.8

Recombinant Anti-CD33 x Anti-CD16 x CD123 Trispecific Antibody (Single-chain Triplebody)

SCTB-104 200μg Ask for price
Description: A trispecific antibody that is expressed as a single chain with three scFv units, two distal binding sites for CD33 and CD123, a central site for CD16. This BsAb can retarget NK cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML) therapy.

Anti-EMMPRIN / CD147 Reference Antibody (Centocor anti-CD147)

E24CHA651 100 μg
EUR 225
Description: Available in various conjugation types.

Anti-OX2R / CD200R1 Reference Antibody (Janssen anti-CD200R1)

E24CHA149 100 μg
EUR 225
Description: Available in various conjugation types.

Anti-CD16/CD32, Rabbit IgG Antibody

A1107-200 each
EUR 874.8

Anti-CD28 (lumretuzumab)-MC-MMAF ADC

ADC-W-2278 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a MC linker to MMAF

Anti-CD28 (lumretuzumab)-SMCC-DM1 ADC

ADC-W-2276 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a SMCC linker to DM1

Anti-CD28 (lumretuzumab)-SPDB-DM4 ADC

ADC-W-2277 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a SPDB linker to DM4

Anti-CD3-ZETA / CD247 antibody

STJ73100 100 µg
EUR 430.8

Anti-CD44v4 Antibody (Clone CD44v4/1219)

A1526-100 each
EUR 574.8

Anti-CD44v6 Antibody (Clone CD44v6/1246)

A1527-100 each
EUR 574.8

Anti-CD44v9 Antibody (Clone CD44v9/1459)

A1528-100 each
EUR 574.8

Anti-CD20 CAR Lentivirus (Clone Leu-16 ScFv-CD8-4-1BB-CD3ζ)

78606 50 µl
EUR 1095
Description: The anti-CD20 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD20 (clone Leu-16) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains .

Anti-CD28 Antibody [37.51], Unconjugated-25ug

QAB99-25ug 25ug
EUR 138

Anti-CD28 Antibody [37.51], Unconjugated-100ug

QAB99-100ug 100ug
EUR 178.8

Anti-CD28 Antibody [37.51], Unconjugated-500ug

QAB99-500ug 500ug
EUR 279.6

Goat anti-CD3-ZETA / CD247 Antibody

dAP-3199 50ug
EUR 264.6

Anti-CD28 Antibody [37.51], Qfluor 630-100ug

QAB99-QF630-100ug 100ug
EUR 270

Anti-CD28 Antibody [37.51], Qfluor 630-500ug

QAB99-QF630-500ug 500ug
EUR 372

Anti-CD28 (lulizumab pegol)-MC-MMAF ADC

ADC-W-2332 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a MC linker to MMAF

resDetect™ Anti-CD28 Antibody ELISA Kit

CRS-A014 96tests
EUR 652.7
Description: Similar to CD3 antibody, CD28 antibodies also can be used to stimulate the proliferation and activation of T cells in CIK cell therapy. Under the cooperation of other cytokines, such as IL2 and IL1a, CIK cells with rapid proliferation, high tumoricidal activity, broad tumor killing spectrum and non-MHC-restricted tumor killing characteristics are generated,which has significant effects on the treatment of cancer, chronic leukemia, liver disease and neurological diseases. Obviously, It is necessary to control the residues of raw materials in the final cell therapy products.

Anti-CD30/ TNFRSF8 Antibody Clone CD30/412, Unconjugated-20ug

943-MSM1-P0 20ug
EUR 279.6

Anti-CD28 (lulizumab pegol)-SMCC-DM1 ADC

ADC-W-2330 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a SMCC linker to DM1

Anti-CD28 (lulizumab pegol)-SPDB-DM4 ADC

ADC-W-2331 1mg Ask for price
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a SPDB linker to DM4

The RNA Modification Database is staying up-to-date with important enhancements being ready for inclusion throughout the subsequent 12 months and the next 12 months. The expanded future position of The RNA Modification Database shall be to function a major info portal for researchers throughout the whole spectrum of RNA-related analysis. Most not too long ago, partly pushed by NIH roadmap initiatives, issues have arisen as to what tool-like means within the seek for chemical instruments to probe biology house.